RxDoctor Payments Data

Charles White, MD

Internal Medicine · Columbia, SCNPI 1215900220

Payments from drug & device makers

$2,348in general payments, 2019–2025

Across 89 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$467
  • Regeneron Healthcare Solutions, Inc.$257
  • Insmed, Inc.$255
  • Boehringer Ingelheim$230
  • Sanofi$189
  • GSK$180
  • plus $771 from 15 others

What the payments were for

  • Food & beverage$2,09889%
  • Education$25011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,348 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$114,781
Medicare patients
79
Services billed
1,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$50,859
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr50$25,785
Stiolto RespimatTiotropium Br/Olodaterol Hcl37$19,207
Spiriva RespimatTiotropium Bromide32$16,666
SymbicortBudesonide/Formoterol Fumarate28$9,443
Breo ElliptaFluticasone/Vilanterol24$9,381
Combivent RespimatIpratropium/Albuterol Sulfate12$7,969
Incruse ElliptaUmeclidinium Bromide17$7,155
Albuterol Sulfate HfaAlbuterol Sulfate110$3,491
Wixela InhubFluticasone Propion/Salmeterol21$3,065
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,026
Montelukast Sodium45$344
Fluticasone Propionate16$319
Omeprazole11$128
Prednisone11$19

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$180$93,181161 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$230$43,84281 claims
AstraZenecaSymbicort$467$9,44328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →